What is the recommended dosing regimen for voriconazole, including loading and maintenance doses for adults and children and adjustments for hepatic impairment and renal failure?

Voriconazole Dosing Recommendations

For adults with invasive aspergillosis or other serious fungal infections, initiate voriconazole with a loading dose of 6 mg/kg IV every 12 hours for two doses (first 24 hours), followed by a maintenance dose of 4 mg/kg IV every 12 hours or 200 mg orally every 12 hours. 1, 2

Adult Dosing by Indication

Standard Dosing (≥40 kg body weight)

Loading Dose:

• 6 mg/kg IV every 12 hours for 2 doses (day 1 only) 1, 2

Maintenance Dose:

• IV: 4 mg/kg every 12 hours 1, 2
• Oral: 200 mg every 12 hours 1, 2

For patients <40 kg:

• Oral maintenance: 100 mg every 12 hours 2

Indication-Specific Dosing

Invasive Aspergillosis: Standard dosing as above 1, 3

Candidemia/Deep Tissue Candida: Standard dosing as above 2

Esophageal Candidiasis:

• No loading dose evaluated
• 200 mg orally every 12 hours 2

Scedosporiosis/Fusariosis: Standard dosing as above 1, 2

Pediatric Dosing

For pediatric patients aged 12-14 years weighing ≥50 kg and those ≥15 years: Use adult dosing 2

For children 2 to <12 years:

• Loading dose: Not adequately studied 1
• Maintenance dose: 7 mg/kg IV every 12 hours (higher than adults due to accelerated metabolic clearance) 1, 4
• The European Medicines Agency recommends 7 mg/kg twice daily to achieve plasma levels comparable to adults 1

Important pediatric considerations:

• Children exhibit higher clearance and require higher weight-based doses than adults 4, 5
• Wide inter- and intraindividual variability exists, with 56% of children on 7 mg/kg having trough levels outside the therapeutic range 4
• Therapeutic drug monitoring is particularly important in pediatric patients 4, 5

Hepatic Impairment Adjustments

For mild to moderate hepatic impairment (Child-Pugh Class A and B):

• Use half the standard maintenance dose 6, 2
• Loading dose: 200 mg IV or orally every 12 hours 7
• Maintenance: 75 mg every 12 hours or 150 mg every 24 hours (IV or oral) 7

For severe hepatic impairment (Child-Pugh Class C):

• Use one-quarter of the standard maintenance dose 7
• Loading dose: 200 mg IV or orally every 12 hours 7
• Maintenance: 50 mg every 12 hours or 100 mg every 24 hours (IV or oral) 7

Critical hepatic dosing considerations:

• Voriconazole is the only triazole requiring dose reduction for hepatic impairment 8
• CYP2C19 genotype has no significant effect on voriconazole concentrations in Child-Pugh C patients 9, 7
• The threshold for adverse events is 5.12 mg/L 7
• Voriconazole clearance decreases dramatically: 7.59 L/hour (normal) → 1.86 L/hour (Child-Pugh A/B) → 0.93 L/hour (Child-Pugh C) 7

Renal Impairment Adjustments

For moderate to severe renal impairment (creatinine clearance <50 mL/min):

• Avoid IV voriconazole due to cyclodextrin vehicle accumulation 1, 2
• Oral voriconazole does not require dose adjustment 1, 2
• The cyclodextrin vehicle (SBECD) accumulates in renal insufficiency, though consequences remain uncertain 1

Important renal considerations:

• Oral bioavailability is 96% and unaffected by renal function 2
• Renal impairment does not affect voriconazole pharmacokinetics itself 10
• SBECD clearance correlates linearly with creatinine clearance (r² = 0.857) 10
• Retrospective data suggest IV voriconazole may be tolerated in renal impairment, but caution is advised 8, 10
• The relative benefits versus uncertain risks must be determined on an individual basis for IV use in renal failure 1

Dose Adjustments Based on Therapeutic Drug Monitoring

Target trough concentration: 1-5.5 mg/L (some sources suggest <6 mg/L) 9, 7

If trough is subtherapeutic (<1 mg/L):

• Adults: Increase dose by 25-50% 9
• Pediatrics: Increase by 1-2 mg/kg or by 50% 9

If trough is supratherapeutic (>5.5 mg/L):

• Adults: Decrease dose by 25-50% 9
• Pediatrics: Reduce by 1 mg/kg or hold 1 dose and decrease subsequent dose by 25% 9

If drug-related adverse event occurs:

• Hold 1 dose, decrease subsequent dose by 50% 9

Critical Clinical Considerations

Route of administration:

• IV therapy is recommended initially to approximate the landmark trial results 1
• Oral bioavailability is excellent (96%), allowing transition when clinically appropriate 2
• Oral absorption decreases with high-fat meals (34% reduction in Cmax for tablets, 58% for suspension) 8, 2

Steady-state achievement:

• With loading dose: Near steady-state by 24 hours 2, 11
• Without loading dose: Steady-state by day 6 in most patients 2

Common pitfalls:

• Voriconazole exhibits nonlinear pharmacokinetics with saturable metabolism 1, 2
• Increasing oral dose from 200 mg to 300 mg every 12 hours produces approximately 2.5-fold (not 1.5-fold) increase in exposure 2
• High interindividual variability exists due to CYP2C19 genetic polymorphism 1
• CYP2C19 polymorphisms are more common in Asian populations 1
• Routine genetic testing is not currently recommended from a pharmacoeconomic perspective 9

Drug interactions:

• Voriconazole is both substrate and inhibitor of CYP2C19, CYP2C9, and CYP3A4 1
• Review all concomitant medications for potential interactions 1
• Particular caution with anticonvulsants in CNS aspergillosis 1, 3

Inflammation effects:

• Higher CRP levels (>100 mg/L) correlate with reduced metabolic capacity due to CYP450 downregulation 12
• This "phenoconversion" may mask genotype effects during acute illness 12

Therapeutic drug monitoring is strongly recommended given the wide variability in exposure, nonlinear pharmacokinetics, and narrow therapeutic window 1, 9, 4.